Continuing The Conversation: The Future Of Reimbursement For Cell And Gene Therapies

Cell and gene therapies were expected to pose significant payer challenges due to the tension between their potentially transformational, long-term patient benefits from single or infrequent treatments and the limited clinical data available at launch. In reality, however, several high-cost cell and gene therapies have achieved rapid and broad reimbursement to date across major payer bodies.

Nevertheless, the cell and gene therapies environment is changing, with an increasing focus toward larger indications with relatively lower unmet needs alongside the potential for increased competition with multiple cell and gene therapies launching in the same indication. In this white paper, we explore how payers will respond to a changing cell and gene therapies landscape and how innovative reimbursement strategies for these therapies might evolve.